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A B S T R A C T
Introduction: Delaying childbearing has led to an increased incidence of age-related female infertility. The
interest in herbal medicine as an option for fertility care extends to many countries. The aim of this study
was to evaluate the outcome of Korean herbal medicine treatment for women with infertility aged 35
years by calculating the clinical pregnancy and live birth rate through a retrospective analysis.
Methods: A retrospective analysis was carried out using computerized charts for 270 infertile women,
over the age of 35 years receiving Korean herbal treatment from the Happysaem Korean Medicine Clinic,
between 2011 and 2012. The main outcome measures were clinical pregnancy and live birth rates.
Secondary outcome measures included the predictors of pregnancy success and treatment period/cost
until pregnancy was achieved.
Results: Our results revealed that clinical pregnancy and live birth rates after Korean herbal treatment
were 44.4% and 26.3%, respectively, in totality, 49.0% and 30.0%, respectively, in the 35–39 years group,
and 31.4% and 15.7%, respectively, in the 40–46 years group. The clinical pregnancy rates were 44.0% in
the Korean herbal treatment group and 43.4% in the Korean herbal treatment + western treatment group.
The live birth rates were 23.5% in the Korean herbal treatment group and 31.3% in the Korean herbal
treatment + western treatment group. The mean treatment duration was 11.26  5.02 weeks and average
cost for Korean herbal treatment was $1320  600.
Conclusions: Our retrospective study suggests that management of infertile women 35 years with
Korean herbal treatment can be effective and economical.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Today, women all over the world tend to delay childbearing due
to postponement of marriage, professional pursuits, or educational
achievements. The birth rate for women over the age of 35 years
has risen continuously. It is reported that the birth rate for women
35 years has increased from approximately 35 births per 1000
women in 1990–61.5 in 2014 [1], and about 20% of women have
their ﬁrst child after the age of 35 in the USA [2]. These
demographic shifts towards delayed childbearing may have led
to the increase in age-related female infertility. According to a
classic report on age-related infertility, the percentage of married* Corresponding author.
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4.0/).women who remain childless increases progressively: 6% at age
20–24 years, 9% at age 25–29 years, 15% at age 30–34 years, 30% at
age 35–39 years, and 64% at ages above 40 years [3]. Additionally, a
prospective fecundability study has indicated that the infertility
rate increases from 13 to 14% for women aged 27–34 to 18% for
women aged 35–39 [4].
Most women who need fertility treatment are referred for
costly conventional management with assisted reproductive
technologies (ART) such as in vitro-fertilization (IVF). It is reported
that the average cost of a single fresh IVF cycle is $4950 (USD),
ranging from $1800–$13,000 in 32 middle and high-income
countries [5]. However, the success rates of ART start declining
from the age of 35 years [6]. According to a large-scale research
study, women aged 35–39 years and 40–44 years undertaking ART
had only 24% and 11.2% probability, respectively, of conceiving,
compared with 31.4% for women aged 30–34 years [7]. Therefore,le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
S. Heo et al. / European Journal of Integrative Medicine 8 (2016) 670–675 671ART could become a more serious ﬁnancial burden for women with
infertility aged 35 years and above.
Meanwhile, the use of traditional herbal medicine as an
alternative for fertility care is becoming more widespread due
to failure to conceive [8], and the efﬁcacy of traditional herbal
medicine is increasingly being recognized [9,10]. According to a
systematic review, patients receiving herbal treatment had a 1.74
times higher probability of pregnancy compared with those
receiving western medicine therapy [10]. Women aged 35 years
are showing an interest in receiving herbal medicine treatment
because of the low probability of success of ART. However, very few
studies have investigated the effectiveness of herbal treatment in
women with infertility aged 35 years.
Therefore, the aim of this study was to evaluate the outcome of
Korean herbal medicine (KHM) treatment for women with
infertility aged 35 years by calculating the clinical pregnancy
and live birth rate through a retrospective analysis. In addition, we
sought to investigate the predictors of pregnancy with KHM
treatment. Medical costs per successful pregnancy were also
evaluated.
2. Materials and methods
2.1. Subjects
The study participants were selected from among the 1332
patients who visited Happysaem Korean Medicine Clinic between
January 1, 2011 and December 31, 2012 with the goal of conceiving.
The inclusion criteria were as follows: women aged 35 years,
KHM use of more than 4 weeks, no infertility factor in their male
partner, and available follow-up information. Infertility was
deﬁned as the inability to conceive for six months or longer after
having a normal married life [11]. All patients received KHM
treatment from Happysaem Korean Medicine Clinic, although
those who received combined western treatments (WT), including
ovulation induction (OI), intrauterine insemination (IUI), or IVF at
other institutes, were also included (Fig. 1). Finally, the charts of
270 patients were retrospectively evaluated for clinical pregnancyFig. 1. Flow chart of therates (CPR), live birth rates (LBR), predictors of pregnancy success,
and medical costs incurred during the treatment course.
2.2. Treatment
KHM refers to a decoction prescribed individually based on
syndrome differentiation according to traditional Korean medicine
theory. All patients were instructed to take herbal decoctions three
times a day following a meal. Subject who received WT in addition
to KHM, mainly used KHM for treatment preparation about 12
weeks before IVF or IUI, and in some cases were provided KHM
following embryo transfer to support implantation and protect the
fetus. The other combination was medication with ovulation-
inducing agents such as clomiphene citrate in addition to KHM
without undergoing IVF or IUI. Other traditional Korean medicine
treatments such as acupuncture, moxibustion, or cupping were not
used. The representative herbal prescriptions were Chokyungsoyo-
san, Chokyungonshin-tang, and Guichulleekyung-tang. The herbal
remedies we used and detailed compositions of prescriptions are
shown in Appendix A.
2.3. Follow-up and assessment
Happysaem Korean Medicine Clinic follows the practice of
performing follow-up visits and telephonic follow-up for patients
receiving KHM treatment, to check on pregnancy and birth status.
Accordingly, patients with veriﬁable follow-up between 6–12
months after the initial visit were included in the study.
Data related to baseline characteristics including age, duration
of infertility, causes and type of infertility, previous ART experi-
ence, regularity of menstrual cycle length, and body mass index
(BMI) were extracted. The main outcomes were CPR and LBR for
the overall study population and for individual groups (KHM
treatment only [KHM group] and KHM treatment combined with
western treatment [KHM + WT group]). Data on the total medical
costs (consultation fee and KHM costs) during the treatment
course and the total treatment period was collected and adverse
events examined. analyzed patients.
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identiﬁed on ultrasound 5–7 weeks after KHM treatment, and live
birth was deﬁned as the birth of at least one live born infant of >20
weeks gestation. The birth of twins was considered as one live
birth.
Causes of infertility were classiﬁed as being related to
ovulation, structural factors related to the fallopian tubes and
pelvis, uterus and cervix, ovaries, or an unexplained cause, based
on the patient statements regarding previous western medical
examinations. For cases in which western medical examination
was not performed, the cause of infertility was classiﬁed as
unknown (no examination).
This study was approved by the Institutional Review Board of
the Kyung Hee University Korean Medicine Hospital (approval
number: KOMCIRB-150622-HR-020). Signed informed consent
forms from participants were granted an exemption due to
research design by the Institutional Review Board of the Kyung Hee
University Korean Medicine Hospital.
2.4. Statistical analysis
Frequency analysis and descriptive statistics were performed to
achieve a CI of 95%. For intergroup analyses, a chi-squared test was
used for binomial analysis, while a t-test was used for continuous
variables when the assumption of normality was satisﬁed.
Otherwise, the Mann–Whitney U test was used. Predictors of
clinical pregnancy were analyzed using a multivariate logistic
regression model adjusted for covariates. All statistical analyses
were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). A p
value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. Patient characteristics
A total of 270 women with infertility aged 35 years (range:
35–46 years), with an average infertility duration of 38.12  30.07
months, were included in our analysis. Table 1 shows that the
majority of causes of infertility were unexplained causes,
endometriosis, or ovulatory dysfunction. The mean number ofTable 1
Characteristics of the patients included in the study.
Total
(n = 270)
Age (y) 37.72  2.51
(35–46)
Duration of infertility (mo) 38.12  30.07
(6–168)
Infertility diagnosis (%) 
Ovulatory dysfunction 39 (14.4) 
Tubal and pelvic factors 19 (7.0) 
Endometriosis 47 (17.4) 
Ovarian factors 14 (5.2) 
Unexplained 132 (48.9) 
Unknown cause 19 (7.0) 
Obstetrics history (%) 
Primary infertility 115 (42.6) 
Secondary infertility 155 (57.4) 
Regularity of menstrual cycle length (%) 
Regular 220 (81.5) 
Irregular 50 (18.5) 
Previous ART experience (n) 2.38  3.09
(0–17)
BMI(kg/m2) 21.10  2.58
(15–29)
KHM = Korean herbal medicine, WT = western treatment, ART = assisted reproductive te
aUnivariate analysis, comparison between ‘KHM’ and ‘KHM + WT’.previous ART treatments was 2.38  3.09 (range: 0–17), and the
mean BMI was 21.10  2.58 kg/m2.
In a comparison between the KHM and KHM + WT groups,
signiﬁcant differences were found in these characteristics: age
(p = 0.021), obstetrical history (p = 0.021), and number of previous
ART treatments (p < 0.001).
3.2. Clinical pregnancy rates and live birth rates
As shown in Table 2, CPR and LBR for the overall study
population were 44.4% and 26.3%, respectively. We divided
patients into groups by age: 35–39 years and 40–46 years, because
age >40 years is recognized as a more difﬁcult age to conceive. We
evaluated CPR and LBR in each group. The results showed that CPR
and LBR were 49.0% and 30.0%, respectively in the 35–39 years
group, and 31.4% and 15.7%, respectively, in the 40–46 years group.
CPR was 44.0% in the KHM group and 43.4% in the KHM + WT
group; LBR was 23.5% in the KHM group and 31.3% in the KHM + WT
group. If 97 women who we could not contact 6–12 months post
treatment were assumed to fail, CPR and LBR were 32.7% and 19.3%,
respectively.
3.3. Predictors for pregnancy
After the univariate analysis, a multivariate logistic regression
analysis was performed using backward stepwise only with
variables for which the p value >0.2. We found that the predictors
of pregnancy were age, duration of infertility, regularity of
menstrual cycle length, and obstetrical history. Women aged 35
years or above were 15% less likely to achieve clinical pregnancy
with a 1-year increase in age (odds ratio 0.85; 95% CI 0.76–0.94).
The duration of infertility also affected the success of the
treatment. A 1-year increase in the infertility period decreased
the chances of pregnancy by 12% (odds ratio 0.88; 95% CI 0.79–
0.98). Women with infertility with irregular menstrual cycles were
50% less likely to conceive compared to women with a regular
menstrual cycle (odds ratio 0.50; 95% CI 0.25–0.98). Women with
previous pregnancies had a 2-fold higher chance of conceiving
than women who had never been pregnant before (odds ratio 2.09;
95% CI 1.24–3.52). Results are summarized in Table 3.KHM
(n = 166)
KHM + WT
(n = 99)
P valuea
37.47  2.34
(35–46)
38.19  2.73
(35–44)
0.021
36.87  29.8
(6–134)
40.64  30.69
(6–168)
0.155
0.314
26 (15.7) 12 (12.1)
10(6.0) 9 (9.1)
29(17.5) 15 (15.2)
5 (3.0) 9 (9.1)
79 (47.6) 52 (52.5)
17(10.2) 2 (2.0)
0.021
60 (36.1) 53 (53.5)
106 (63.9) 46 (46.5)
0.378
138 (83.1) 79 (78.8)
28 (16.9) 21 (21.2)
2.02  3.05
(0–15)
2.97  3.08
(0–17)
<0.001
21.16  2.55
(15–29)
20.96  2.55
(15–29)
0.572
chnologies, BMI = body mass index.
Table 2
Pregnancy rates and live birth rates.
Pregnancies (n) Pregnancy rate (%) Deliveries (n) Live birth rate (%)
Total (n = 270) 120 44.4 71 26.3
35–39 (n = 200) 98 49.0 60 30.0
40–46 (n = 70) 22 31.4 11 15.7
KHM (n = 166) 73 44.0 39 23.5
35–39 (n = 133) 63 47.4 34 25.6
40–46 (n = 33) 10 30.3 5 15.2
KHM + WT (n = 99) 43 43.4 31 31.3
35–39 (n = 63) 32 50.8 25 39.7
40–46 (n = 36) 11 30.6 6 16.7
KHM = Korean herbal medicine, WT = western treatment.
Table 3
Results of a multivariate logistic regression analysis of the predictors of pregnancy.
Univariate Multivariate
OR (95% CI) P value AOR (95% CI) P value
Age (y) 0.86 (0.77–0.95) 0.003 0.85 (0.76–0.94) 0.002
Duration of infertility (y) 0.88 (0.79–0.98) 0.015 0.88 (0.79–0.98) 0.017
Previous ART experience (n) 0.96(0.88–1.04) 0.281
BMI (kg/m2) 0.94 (0.85–1.04) 0.205
Type of treatment
KHM (ref) 1.00
KHM + WT 0.98 (0.59–1.62) 0.931
Regularity of menstrual cycle length
Regular (ref) 1.00 1.00
Irregular 0.59 (0.31–1.11) 0.102 0.50 (0.25–0.98) 0.045
Obstetrics history
Primary infertility (ref) 1.00 1.00
Secondary infertility 1.76 (1.08–2.89) 0.025 2.09 (1.24–3.52) 0.05
Infertility diagnosis
Unexplained (ref) 1.00
Ovulatory dysfunction 0.73 (0.35–1.51) 0.393
Tubal and pelvic factors 1.05 (0.40–2.75) 0.925
Endometriosis 0.94 (0.48–1.84) 0.856
Ovarian factors 0.65 (0.21–2.03) 0.456
Unknown cause 1.05 (0.40–2.75) 0.925
KHM = Korean herbal medicine, WT = western treatment, ART = assisted reproductive technologies, BMI = body mass index.
OR = odds ratio, AOR = adjusted odds ratio.
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therapy
The average treatment duration and KHM costs until concep-
tion are presented in Table 4. The mean treatment duration was
11.26  5.02 weeks and average medical cost was $1320  600.
3.5. Adverse events
During the treatment period, 15 patients out of the total 270
(5.6%) showed symptoms of diarrhea (7), mild abdominal pain (2),
dyspepsia (2), sense of distension (2), nausea (1), and heartburn
(1). However, there were no crucial adverse effects on patient
health and all of these symptoms were temporary. There were no
adverse effects on maternal, fetal, or neonatal health.Table 4
Average treatment duration and cost in pregnancy group.
Total
(n = 120)
KHM
(n = 73)
KHM + WT
(n = 43)
Treatment duration (wk) 11.26  5.02 10.90  4.58 11.98  5.70
Cost ($)a 1320  600 1273  554 1423  665
KHM = Korean herbal medicine, WT = western treatment.
a Mean cost: expenses incurred from KHM treatment alone.4. Discussion
In the present study, the CPR and LBR of women aged 35 years
with infertility were 44.4% and 26.3%, respectively, following KHM
treatment. These results show higher success rates than a report of
Korean IVF and ICSI outcomes in 2010 (23.2% CPR per retrieval in
fresh cycle IVF in women aged over 35 years) [12]. The improved
rate of success with KHM is still apparent if we assume that all of
the 97 patients excluded due to unsuccessful follow-up failed to
conceive. In these adjusted rates CPR and LBR were 32.7% and
19.3%, respectively.
There are several reports that pregnancy outcomes after ART in
Asian women are lower compared with those in white women [13–
15]. On the contrary, our ﬁndings suggest that KHM may provide
relatively better outcomes in treating women with infertility aged
35 years. Moreover, women above the age of 40 were found to
have an overall CPR of 31.4% and LBR of 15.7% in our study, higher
than that found in a retrospective review of IVF cycles in women 40
years and above, performed in Singapore (12.3% CPR and 6.7% LBR)
[16]. Accordingly, it is possible that the effectiveness of herbal
medicine on pregnancy, as veriﬁed by previous studies [10,17,18],
may be generalized to women of advanced maternal age whose
chances of a successful pregnancy are low.
Our observations about predictors of pregnancy outcome
indicate that the possibility of conceiving declines with increasing
age and duration of infertility among women aged 35 years and
674 S. Heo et al. / European Journal of Integrative Medicine 8 (2016) 670–675above. These ﬁndings conﬁrm the existing knowledge about the
effects of age [19,20] and duration of infertility [21,22] on
pregnancy. Regularity of menstrual cycle length was also a
predictor of pregnancy success, similar to reports by Kolstad
et al. [23]. Additionally, results indicating that women with
secondary infertility have a higher likelihood of becoming
pregnant than those with primary infertility is in line with
previous research [24]. In comparison, our logistic regression
analysis revealed that cause of infertility, number of previous
unsuccessful ART attempts, combined use of WT, and BMI did not
have an effect on pregnancy outcome. These results may be used as
a basis for counseling patients 35 years old regarding KHM
treatment for infertility.
From an economic perspective, the cost for KHM treatment for
infertility care is relatively low ($1320  600, mean cost incurred
for a successful pregnancy). It has been reported that the out of
pocket costs for individual couples are up to USD 19,000 for the
ﬁrst IVF cycle, and on average USD 7000 for additional cycles in the
USA in 2011 [25]. According to the 2012 policy report, couples
treated with IVF spent an average of USD 2267 in Korea [26]. As the
cost in the present study is the total payment for KHM until
conception, KHM treatment may be more economical compared
with IVF.
The results from this study also show that no serious adverse
events occurred during the treatment period. While 5.6% of
patients exhibited mild symptoms, including diarrhea or mild
abdominal pain, they soon recovered.
To our knowledge, this is the ﬁrst retrospective study that
evaluates pregnancy outcome including LBR and cost of KHM
treatment for women with infertility over the age of 35. Although
we attempted to minimize possible bias by including strict
procedures, including strict enforcement of the inclusion criteria,
our study does have some limitations. First, this is a retrospective
study of the clinical records from a single institute. The records
were based largely on patient statements, without objective
examination values. Secondly, the relatively small number of
subjects at a single center limits our ability to generalize the
effectiveness and economics of KHM to other populations with
infertility. Lastly, we enrolled patients whose charts had available
follow-up results 6–12 months after the ﬁrst visit. Hence, we could
not avoid selection bias in spite of our best efforts. Thus, our results
should be interpreted and applied with caution. Despite these
limitations, the ﬁndings of this retrospective study suggest that
KHM treatment might be beneﬁcial in treating women with
infertility over 35 years of age.
5. Conclusions
Our retrospective study suggests that the use of KHM for the
management of women with infertility who are 35 years old can
be effective and economical. Further investigations with well-
designed and large randomized placebo-controlled trials are
needed to conﬁrm the efﬁcacy of KHM in the treatment of women
with infertility at advanced ages.
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Appendix A.
Korean herbal medicine
formulae
Compositions & dose
(per day)
Frequency of
usage (%)
Chokyunsoyo-san Angelicae Gigantis Radix 8 g,
Atractylodis Rhizoma Alba 8 g, Poria
Sclerotium 8 g, Paeoniae Radix Alba
8 g, Liriopis seu Ophiopogonis Tuber
8 g, Bupleuri Radix 8 g, Moutan
Radicis Cortex 8 g, Zingiberis
Rhizoma Recens 6 g, Glycyrrhizae
Radix et Rhizoma 4 g, Menthae
Herba 4 g
26.08
Chokyungonshin-tang Rehmanniae Radix Preparata 12 g,
Corni Fructus 12 g, Morindae Radix
8 g, Cuscutae Semen 8 g, Angelicae
Gigantis Radix 8 g, Eucommiae
Cortex 8 g, Dioscoreae Rhizoma 8 g,
Rehmanniae Radix 4 g, Alpiniae
Oxyphyllae Fructus 4 g, Poria
Sclertum cum Pini Radix 4 g,
Polygalae Radix 4 g, Dipsaci Radix
4 g, Cnidi Fructus 4 g
9.79
Guichulleekyung-tang Persicae Semen 8 g, Moutan Radicis
Cortex 8 g, Linderae Radix 8 g,
Cinnamomi Cortex 6 g, Cyperi
Rhizoma 8 g, Citri Unshius
PericarpiumImmaturus 8 g,
Sparganii Rhizoma 8 g, Rhizoma
Zedoariae 8 g, Angelicae Gigantis
Radix 8 g, Paeniae Radix Rubra 12 g,
Corydalis Tuber 12 g, Sappan
Lignum 8 g, Carthami Flos 4 g
9.79
Chokyungguibi-tang Angelicae Gigantis Radix 8 g,
Astragali Radix 8 g, Ginseng Radix
4 g, Poria Sclertum cum Pini Radix
8 g, Atractylodis Rhizoma Alba 8 g,
Longan Arillus 8 g, Zizyphi Semen
8 g, Polygalae Radix 4 g, Aucklandiae
Radix 4 g, Glycyrrhizae Radix et
Rhizoma 4 g, Zingiberis Rhizoma
Recens 6 g, Zizyphi Fructus 4 g
8.88
Chokyung tonggyung-tang Angelicae Gigantis Radix 8 g,
Paeoniae Radix Alba 8 g,
Rehmanniae Radix 8 g, Cnidii
Rhizoma 8 g, Cistanchis Herba 8 g,
Morindae Radix 8 g, Cinnamomi
Cortex 6 g, Magnoliae Cortex 6 g,
Mume Fructus 2 g, Cuscutae Semen
8 g, Lycii Fructus 8 g, Rubi Fructus
8 g, Salviae Miltiorrhizae Radix 6 g,
Moutan Radicis Cortex 6 g, Ponciri
FructusImmaturus 6 g, Sappan
Lignum 6 g, Carthami Flos 4 g,
Scutellariae Radix 6 g, Zingiberis
Rhizoma Recens 6 g, Zizyphi Fructus
4 g
8.88
Chokyungtonggyungsamul-
tang
Cyperi Rhizoma 16 g, Glycyrrhizae
Radix et Rhizoma 4 g, Cinnamomi
Cortex 4 g, Cnidii Rhizoma 8 g,
Paeoniae Radix Alba 8 g, Sappan
Lignum 6 g, Angelicae Gigantis
Radix 12 g, Rehmanniae Radix
Preparata 8 g, Rhizoma Zedoariae
6 g, Persicae Semen 4 g, Carthami
Flos 3 g
7.97
Bogibohyul-tang 6.61
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Korean herbal medicine
formulae
Compositions & dose
(per day)
Frequency of
usage (%)
Cnidii Rhizoma 8 g, Artemisiae Argyi
Folium 8 g, Astragali Radix 8 g,
Amomi Fructus 8 g, Asini Corii Colla
8 g, Atractylodis Rhizoma Alba 8 g,
Cyperi Rhizoma 8 g, Citri Unshius
PericarpiumImmaturus 8 g,
Paeoniae Radix Alba 8 g, Ginseng
Radix 4 g, Glycyrrhizae Radix et
Rhizoma 8 g, Angelicae Gigantis
Radix 8 g
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